FeMMe aimed to treat obese women with early-stage endometrial cancer less invasively using a mirena, an intra-uterine device, metformin, the most widely used anti-diabetes drug and a weight-loss program.
In this research project, the mirena was loading with metformin, aiming to treat cancer from inside the uterus. This treatment was far less invasive than a radical hysterectomy and allowed at-risk women to avoid the complications and side effects associated with surgery. It also provided women with the option to retain their reproductive organs and fertility options.
The Femme trial has now been completed. Please find a link to the publication about the results of the feMMe clinical trial – https://doi.org/10.1016/j.ygyno.2021.01.029